Q&A: Taking a Look at President Trump’s Drug Agenda

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2uZSryd on July 14, 2017 at 04:18PM

Stethoscope on moneyFederal Government Relations Practice Group Leader Michael Strazzella and Buchanan, Ingersoll & Rooney shareholder William Garvin sat down for a question-and-answer with Becker’s Hospital Review Editor Laura Dyrda to discuss President Donald Trump’s efforts to slash drug prices.

Garvin during the Q&A said he expects some action to reduce drug prices, but that it was unlikely any executive order would touch on foreign drug imports or “direct negotiation of drug prices with the federal government.”

“The most likely outcome is support for value-based pricing agreements, increased focus on speed up generic drug approvals and allowing the FDA to reprioritize the queue for generic products based on pricing concerns,” Garvin said.

Click here to read the full Q&A on Beckers Hospital Review’s website.